

ASCIA 2014 CONFERENCE

PROGRAM BOOK

25th Annual Conference of the Australasian Society
of Clinical Immunology and Allergy (ASCIA)

Melbourne Convention and Exhibition Centre 10-13 September 2014

ASCIA is the peak professional body of clinical immunology and allergy specialists in Australia and New Zealand and is a member society of the Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI) and the World Allergy Organisation (WAO).

ascia

australasian society of clinical immunology and allergy

www.allergy.org.au

Sponsors and Exhibitors

ASCIA gratefully acknowledges the generous support of the following sponsors:

Diamond Sponsors



Platinum Sponsor



Gold Sponsors



Exhibitors and other Sponsors

Sponsors and exhibitors confirmed at the time of publishing this program book are as follows:

- Abacus-ALS
- Abbott
- AIFA / ASCIA 2015 Conference
- Allergend
- Allergy & Anaphylaxis Australia
- Allergy New Zealand
- Alphapharm
- AusEE
- AMSL/NZMS
- Autoimmune Resource & Research Centre (ARRC)
- Baxter Healthcare
- Centre for Food & Allergy Research (CFAR)
- CSL Behring
- Diagnostic Solutions
- Ego Pharmaceuticals
- ENT Technologies
- GSK
- HAE Australasia
- IDFA
- IDFNZ
- MEDA Pharmaceuticals
- MedicAlert Foundation
- MSD
- National Asthma Council
- Neilmed
- Nestlé Health Science
- Nestlé Nutrition
- Novartis
- Nutricia Advanced Medical
- Danone Nutricia Early Life Nutrition
- Octapharma
- Sapphire Bioscience
- Shire Australia
- Stallergenes
- Takeda
- TAMS
- Werfen Australia

Note: The content of ASCIA 2014 is not influenced by its sponsors or exhibitors

CONTENTS

Sponsors and Exhibitors	1
Welcome	2
Secretariat	3
Program at a Glance	3
Program	4
International Speakers	9
Basten Orator	11
Invited Speakers - Australasia	12
Chairs	12
Information (A-Z)	13
Clinical Grand Rounds: Program	19
Poster Abstracts: Index	20
Exhibition Floorplan	25
Exhibitors	26
Exhibitor Directory	27

On behalf of the Australasian Society of Clinical Immunology and Allergy (ASCIA), I welcome you to the ASCIA 2014 Annual Conference in Melbourne.

I feel certain that the outstanding program for this conference will provide an international standard of continuing professional development for ASCIA members and other health professionals working in the areas of allergy and other immune diseases.

Clinical Associate Professor Richard Loh
ASCIA President

It is a pleasure to welcome you to the ASCIA 2014 Annual Conference, which runs from Wednesday 10th to Saturday 13th September.

The conference includes:

- ASCIA 2014 Allergy and Immunology Update for nurses, dietitians and other health professionals on Saturday 13th September
- ASCIA 2014 Immunopathology Update on Saturday 13th September

The ASCIA 2014 conference program features presentations by several internationally renowned speakers from the USA, UK and Australasia on a range of topics pertinent to allergy and other immune diseases. The international speakers presenting at this conference are as follows:

- **Professor Bobby Gaspar**; Great Ormond Street Hospital, London, UK
- **Professor Robert Lemanske**; University of Wisconsin, USA
- **Associate Professor Kari Nadeau**; Stanford University, California, USA
- **Associate Professor Wayne Shreffler**; Massachusetts General Hospital, USA

This is the first time that the ASCIA Annual Conference has been held at the Melbourne Convention Centre, which is located beside the Yarra River, part of the vibrant and cosmopolitan city of Melbourne.

We trust that whilst you participate in the ASCIA 2014 Conference you will also take the opportunity to enjoy your stay in Melbourne.

Professor Jo Douglass

ASCIA 2014 Conference Chair, on behalf of the Organising Committee:
*Prof Katie Allen, Dr Sara Barnes, Dr Jeremy McComish, Vicki McWilliam,
Dr Kate Nicholls, Prof Robyn O'Hehir, Dr Joanne Smart, Prof Mimi Tang,
Dr Dean Tey, Leone Thiele.*

Program at a Glance

Secretariat

Registrations, Website, Abstracts



Level 2, 120 Clarendon Street,
Southbank, VIC 3006, Australia
PO Box 5005, South Melbourne VIC
3205, Australia
P: 03 9682 0500 | F: 03 9682 0344
Email: registration@ascia2014.com
Website: www.ascia2014.com

Sponsorship, Exhibition, Program



australasian society of clinical immunology and allergy

Suite 238, 117 Old Pittwater Road,
Brookvale, NSW 2100, Australia
PO Box 450 Balgowlah NSW 2093,
Australia
P: 02 8039 2140 | F: 02 8039 2144
Email: education@allergy.org.au
Website: www.ascia2014.com

Wednesday 10 Sept	Thursday 11 Sept	Friday 12 Sept	Saturday 13 Sept	Saturday 13 Sept
Day 1	Day 2	Day 3	Immunopathology Update	Allergy And Immunology Update
JSAC Breakfast Forum Registration	Anti-IgE and Asthma Breakfast Session		ASCIA Laboratory Practice Committee Meeting Registration	ASCIA Nurse and Dietitian Subcommittee Meetings Registration
Food Allergy Plenary	Immune Deficiency Plenary	Biologicals Plenary	Immune Deficiency Symposium	Food Allergy Symposium
Morning Tea	Morning Tea	Morning Tea	Morning Tea	Morning Tea
Origins of Allergy and Asthma Plenary	ASCIA Update; ASCIA AGM	Immune Deficiency Symposium	Autoimmunity Symposium	Concurrent sessions: Allergy nursing programs in Australasia; Food challenges and Food Labelling
Lunch	Lunch	Lunch	Lunch	Lunch
Urticaria Symposium	Poster Rounds	Adolescent Allergy and Immunology Symposium	Hypersensitivity Testing Symposium	Concurrent sessions: SCIg and PID, Transplantation and PID; Workshop
Afternoon Tea	Afternoon Tea	Afternoon Tea	Afternoon Tea	Afternoon Tea
Clinical Grand Rounds Presentations	Immune Regulation Plenary	Poster Rounds	Poster Discussion Session	Poster Discussion Session
Welcome Function	Gala Dinner	Closing Function	Wine and Cheese	Wine and Cheese

Day 1 Program

ASCI A 2014

CONFERENCE

Wednesday 10 September 2014

Melbourne Room 2

07.15–09.00	Registration	
07.15–08.45	Breakfast – JSAC forum for supervisors and trainees Chairs: Dr Tiffany Hughes, Dr Melanie Wong, Dr Jan Sinclair	
08.50–09.00	Welcome from ASCIA President and ASCIA 2014 Chair A/Prof Richard Loh, Prof Jo Douglass	
09.00–10.30	Food Allergy Plenary Chairs: Prof Katie Allen, Prof Dianne Campbell	
09.00–09.45	Mechanisms of food allergen immunotherapy	A/Prof Kari Nadeau
09.45–10.30	Roadmap to rational immunotherapy for food allergy	A/Prof Wayne Shreffler
10.30–11.00	Morning Tea	
11.00–12.30	Origins of Allergy and Asthma Plenary Chairs: Prof Connie Katelaris, Dr Graham Solley	
11.00–11.45	Origins of immunity in early life	Prof Susan Prescott
11.45–12.30	Origins of childhood asthma	Prof Robert Lemanske
12.30–13.30	Lunch	
13.30–15.00	Urticaria Symposium Chairs: Dr Ray Mullins, Dr Karl Baumgart	
13.30–14.00	Urticaria – state of the art management	Dr William Smith
14.00–14.30	Immunology of urticaria	Dr Priscilla Auyeung
14.30–15.00	Autoinflammatory syndromes	Dr Seth Masters
15.00–15.30	Afternoon Tea	
15.30–17.30	Clinical Grand Rounds Presentations (15 presentations by advanced trainees) – see page 19 Chairs: Dr Tiffany Hughes, A/Prof David Fulcher	
17.30–18.30	Welcome Function Melbourne Convention Centre Level 2, Foyer 2.1 - adjacent to Melbourne Rooms 1 and 2	

Day 2 Program

Thursday 11 September 2014

Melbourne Room 2

07.15–09.00	Registration	
07.15–08.45	Breakfast Symposium: Anti-IgE and Asthma Chairs: Dr Shannon Brothers, A/Prof Rob Stirling	
07.30-08.00	Anti IgE in food allergen immunotherapy	A/Prof Kari Nadeau
08.00-08.30	Monoclonal antibodies for asthma	Prof Jo Douglass
08.30-08.45	Discussion	
09.00–10.30	Immune Deficiency Plenary Chairs: Prof Matthew Cook, Prof Mimi Tang	
09.00-09.40	New syndromes in PID the IUIS classification	Prof Bobby Gaspar
09.40-10.05	Evaluation of haemophagocytic lymphohistiocytosis (HLH)	Dr Sharon Choo
10.05-10.30	Treatment of PID with SCIg in Australasia – an update	Dr Melanie Wong
10.30-11.00	Morning Tea	
11.00-12.00	ASCIA Update Chair: Dr Kate Nicholls, Dr Dean Tey	
11.00-11.15	New and updated ASCIA allergy educational resources	Dr Sara Barnes
11.15-11.30	New ASCIA immune deficiency projects, including ASCIA ID Register	Dr Jane Peake
11.30-11.45	ASCIA food allergen challenge protocols and ASCIA FAC Register	Prof Dianne Campbell
11.45-12.00	Allergy Summit and National Allergy Strategy	A/Prof Richard Loh
12.00-13.00	ASCIA Annual General Meeting (AGM) Chair: A/Prof Richard Loh	
13.00-14.00	Lunch	
14.00-15.30	Poster Rounds Panel: Prof Katie Allen, Prof Matthew Cook, Dr Ray Mullins, Prof Robyn O'Hehir, Prof Mimi Tang	
15.30-16.00	Afternoon Tea	
16.00-17.30	Immune Regulation Plenary Chairs: Prof Jo Douglass, A/Prof Richard Loh	
16.00-16.50	Basten Oration: T cell recognition of vitamin metabolites	Prof James McCluskey
16.50-17.30	Synthetic Peptide Immuno-Regulatory Epitopes (SPIRE): the new frontier in allergy therapy	Prof Robyn O'Hehir
18.30-23.30	Gala Dinner Melbourne Aquarium	

Day 3 Program

ASCIA 2014

CONFERENCE

Friday 12 September 2014

Melbourne Room 2

07.30-08.30	ASCIA Immunotherapy Working Party meeting: Room 205 Chair: Dr William Smith	
08.00-09.00	ASCIA Drug Allergy Working Party meeting: Melbourne Room 2 Chair: A/Prof Michaela Lucas	
08.30-09.00	Registration	
09.00-10.30	Biologicals Plenary Chairs: Dr Joanne Smart, Dr Marianne Empson	
09.00-09.45	Biomarker-driven personalised treatment for asthma	Prof Robert Lemanske
09.45-10.30	Gene therapy for severe immunodeficiencies	Prof Bobby Gaspar
10.30-11.00	Morning Tea	
11.00-12.30	Immune Deficiency Symposium Chairs: Dr Jane Peake, Dr Julian Bosco	
11.00-11.30	Neonatal screening for SCID	Prof Bobby Gaspar
11.30-12.00	The first decade of a customised PID genetic testing program in New Zealand	A/Prof Rohan Ameratunga
12.00-12.30	ASCIA transplantation and PID (TAPID) project	Dr Joanne Smart
12.30-13.30	Lunch	
13.30-15.00	Adolescent Allergy and Immunology Symposium Chairs: Dr Sara Barnes, Dr Sam Mehr	
13.30-14.00	SchoolNuts study update	Prof Katie Allen
14.00-14.30	Asthma and allergic disease: changes with ageing	Prof Shyamali Dharmage
14.30-15.00	CVID	Dr Vanessa Bryant
15.00-15.30	Afternoon Tea	
15.30-17.00	Poster Rounds Panel: Dr Maia Brewerton, Prof Dianne Campbell, Prof Jo Douglass, A/Prof Stuart Tangye	
17.00-18.00	Closing Function / Wine and Cheese (including CGR and poster awards) Melbourne Convention Centre Level 2, Foyer 2.1 – adjacent to Melbourne Rooms 1 and 2	
19.00	Concurrent sponsored dinners (see page 14)	

Note regarding Poster Rounds on Thursday and Friday afternoons:

- Posters will be allocated a display number which corresponds to an allotted poster round session
- Presenting authors need to check the poster boards for their poster location and must be present with their poster at the time of their allotted poster round session

Immunopathology Update Program

Saturday 13 September 2014

Room 203

07.40-08.20	ASCIA Laboratory Practice Committee meeting Chair: Louise Wienholt	
08.00-08.25	Registration	
08.25-08.30	Welcome and Introduction Dr Jeremy McComish, Dr Kate Nicholls	
08.30-10.30	Immune Deficiency Symposium Chairs: Dr Sharon Choo, Louise Wienholt	
08.30-09.10	Standardising FACS in PID	A/Prof David Fulcher
09.10-09.50	Functional diagnosis in PID	A/Prof Stuart Tangye
09.50-10.30	Genomic diagnosis in PID	Prof Matthew Cook
10.30-11.00	Morning Tea	
11.00-12.30	Autoimmunity Symposium Chairs: Dr Andrew McLean-Tooke, Dr Jeremy McComish	
11.00-11.30	DFS-70	Louise Weinholt
11.30-12.00	New diagnostic guidelines and emerging therapies for coeliac disease	Dr Jason Tye-Din
12.00-12.30	Autoimmune myositides	Dr Pravin Hissaria
12.30-13.30	Lunch	
13.30-15.00	Hypersensitivity Symposium: Recombinant Allergens Chairs: Dr Kate Nicholls, Dr Michael O'Sullivan	
13.30-14.00	Food	Dr Sam Mehr
14.00-14.30	Pollens	Dr Janet Davies
14.30-15.00	Venoms	A/Prof Bob Heddle
15.00-15.30	Afternoon Tea	
15.30-17.00	Poster Discussion Session Chairs: Dr Priscilla Auyeung, Dr Maia Brewerton, Dr Andrew McLean-Tooke	
17.00-18.00	Wine and Cheese (including poster awards) Melbourne Convention Centre	

Allergy and Immunology Update Program

Saturday 13 September 2014

Rooms 204, 205

07.45-08.45	ASCIA subcommittee meetings for nurses and dietitians (concurrent) Chairs: Pam Hudson, Ingrid Roche	
08.00-08.50	Registration	
08.55-09.00	Welcome and Introduction Room 204 Leone Thiele, Vicki McWilliam	
09.00-10.30	Food Allergy Symposium Chairs: Nina Kingon, Rebecca Gibson	
09.00-09.30	Psychological impact of food allergy and anaphylaxis	Olivia Keene
09.30-10.30	CFAR and MCRI food allergy research project update	Leone Thiele, Vicki McWilliam, Nadine Bertalli
10.30-11.00	Morning Tea	
11.00-12.30	Concurrent Sessions	
11.00-12.30	Nurses: Allergy Nursing Programs in Australasia – oral presentations Room 204 Chairs: Leone Thiele, Helen Czech, Pam Hudson	
11.00-12.30	Dietitians: Food Challenges and Food Labelling Room 205 Chair: Vicki McWilliam	
11.00-11.30	The role of baked egg and milk challenges – evidence and future applications	Merryn Netting
11.30-12.00	Precautionary labelling and food allergies – an update	Maria Said
12.00-12.30	Management of food allergies in food service and food businesses – practical aspects, roles and responsibilities	Ingrid Roche
12.30-13.30	Lunch	
13.30-15.00	Concurrent Sessions	
	Nurses: Room 204 Chairs: Jan Belcher, Marry Moussa	
13.30-14.15	Oral presentations on SClg programs for PID throughout Australasia	Noelene Davies, Susie Lester Simone Stephens, Anastasia Wilson
14.15-15.00	An overview on transplantation and PID	Dr Theresa Cole
	Dietitians: Room 205 Chair: Ingrid Roche	
13.30-15.00	Workshop session: Exploring the application of exclusion diets for food allergy diagnosis	Kathy Beck, Anna Richards Vicki McWilliam
15.00-15.30	Afternoon Tea	
15.30-17.00	Poster Discussion Session Room 204 Chairs: Christine Collins, Wendy Stuart-Smith	
17.00-18.00	Wine and Cheese (including poster awards) Melbourne Convention Centre	

International Keynote Speakers

Prof Bobby Gaspar, PhD, MRCP(UK), MRCPCH

Professor of Paediatrics and Immunology, UCL Institute of Child Health

Honorary Consultant in Paediatric Immunology, Great Ormond Street Hospital



Bobby Gaspar is a physician/scientist working in paediatric immunology at the Institute of Child Health (ICH) and Great Ormond Street London. He initially trained in paediatrics and then became interested in primary immunodeficiencies at an early stage in his career and undertook a PhD at the Molecular Immunology Unit at ICH. From there he has continued his academic and clinical career.

His interests are in many different aspects of primary immunodeficiency including understanding the molecular and cellular defects and disease pathogenesis, bone marrow transplantation for severe immunodeficiencies and the development of gene and cell therapy for these conditions. Over the last decade, his team have conducted clinical trials that have shown that gene therapy can successfully correct the immune defect in specific immunodeficiency conditions. He is also leading UK and European initiatives for newborn screening for severe combined immunodeficiency.

Chairman, Clinical Working Party of ESID 2004 - 2008

Chairman, ESID BMT and Gene therapy Working party 2008 - 2013

Chairman EBMT Inborn Errors Working party 2008 - 2013

Member, International Committee, American Society of Gene Therapy, 2008 - present day

Chair, IUIS PID - Expert committee 2013 - present day

Chair, International Committee, American Society of Gene Therapy, 2013 - present day

Deputy Editor - Molecular therapy 2013 onwards

Chairman, Medical Advisory Panel - International Patient Organisation for Primary Immunodeficiencies, 2013 onwards

Member, Medical Advisory Panel - PID-UK, 2013 onwards

Member, Medical Advisory Panel - Ataxia Telangiectasia Society, 2013 onwards

Professor Bobby Gaspar's travel has been supported by an unrestricted educational grant from CSL Behring.

Professor Robert F. Lemanske, Jr., M.D.

University of Wisconsin School of Medicine



Robert F. Lemanske, Jr., M.D., is Professor of Pediatrics and Medicine at the University of Wisconsin School of Medicine and Public Health in Madison, where he is Head of the Division of Pediatric Allergy, Immunology, and Rheumatology. He received his degree in medicine from the University of Wisconsin Medical School (1975) and his pediatric residency training at the University of Wisconsin Hospitals (1975-78). His allergy and immunology training was performed both at the University of Wisconsin (1978-80) and the National Institute of Allergy and Infectious Diseases in Bethesda, Maryland (1980-83). He is Board certified in both Pediatrics and Allergy and Immunology. He is currently the Chair of the Allergy and Immunology Conjoint Program at the University of Wisconsin School of Medicine and Public Health and the Director of the Morris Institute for Respiratory Research.

Dr. Lemanske has published his research in the *Journal of Immunology*, *Journal of Allergy and Clinical Immunology*, *New England Journal of Medicine*, *Journal of the American Medical Association*, *Pediatric Research*, *Journal of Pediatrics*, *American Review of Respiratory and Critical Care Medicine*, and *Immunology*. In addition, he has co-edited three text books and contributed over 60 chapters to various textbooks. Dr. Lemanske has been a national and international speaker on numerous occasions and has received honorary lectureships including the John M. Sheldon, M.D. (AAAAI) and Richard Talamo, M.D. (Johns Hopkins University) memorial lectureships, and the Sheldon Siegel, M.D. lectureship (AAAAI) twice (1992, 2003).

He has served on the editorial Boards of the *Journal of Allergy and Clinical Immunology* and *Pediatric Allergy and Immunology*, and was a director (1994-2000) and Chair (2000) of the American Board of Allergy and Immunology. He was elected and served on the Board of Directors of the AAAAI from 2001-2004. He was appointed to the National Heart Lung and Blood Institute's Advisory Council for decisions regarding extramural funding of basic and clinical research (2003-2007). He also has served on the expert panel for the development of guidelines for the treatment of childhood asthma in Canada and the United States (National Asthma Education and Prevention Program) (NAEPP) and is currently a member of the Scientific Committee of the National Asthma Education and Prevention Program.

While a Fellow of both the American Academy of Allergy, Asthma & Immunology and the American Academy of Pediatrics, Dr. Lemanske is also a member of the American Thoracic Society, the American Association of

Immunologists, and the Society for Pediatric Research. Honors Dr. Lemanske has received include the NIAID Allergic Disease Academic Award and membership in the Society for Pediatric Research.

In 2011, Dr. Lemanske was named to the Top Doctors list published in U.S. News and World Report. His research interests have focused primarily on the pathophysiology and treatment of asthma including mechanisms underlying pulmonary late phase reactions, virus-induced airway dysfunction, and asthma inception in infants and young children.

Associate Professor Kari C. Nadeau, M.D., Ph.D.

Stanford University School of Medicine



After graduating from Haverford College (summa cum laude) with a degree in biology, Dr. Nadeau attended Harvard Medical School via the Medical Scientist Training Program (NIH), and received a PhD in Biological Chemistry and Molecular

Pharmacology and an MD in 1995. She then performed an internship and residency in pediatrics at the Children's Hospital Boston, Harvard Medical School. From 1998 to 2002, she worked in the field of biopharmaceuticals and led clinical research to obtain FDA approval for two biologics in the field of Autoimmunity and Oncology, respectively.

From 2003-2006, Dr. Nadeau was a fellow in Asthma, Allergy and Immunology at the Stanford/UCSF program under Dr. Umetsu and Dr. Avila. During this time, she also did a postdoctoral fellowship in human immune tolerance mechanisms in asthma and allergy. In 2006, Dr. Nadeau was appointed to the Stanford University School of Medicine with appointments in Pediatrics and Otolaryngology. She is a board certified specialist in Allergy, Asthma, and Immunology for both adult and pediatric patients.

She established the Stanford Alliance for Food Allergy Research in 2010, which she directs. She currently holds an endowed faculty position under the Nadissy Family Foundation. Dr. Nadeau has served as a reviewer for NIH Study Sections, and a member of the American Lung Association Medical Board, CA. She serves on the Environmental Health Policy committee for the American Thoracic Society and is a Fellow in the American Academy of Allergy, Asthma and Immunology. She has authored or co-authored more than 80 original papers, and has maintained an interest in the study of immune mechanisms in allergy and asthma for more than 20 years.

Her laboratory focuses on the study of immunological mechanisms involved in the cause, diagnosis, and therapy for allergy and asthma. The laboratory has three main focus areas:

- 1) Studying the role of environmental exposures in impairing natural immune tolerance and in promoting allergy and asthma,
- 2) Determining the interactions of regulatory T cells, dendritic cells, and effector allergy cells (basophils) in mediating possible immune tolerance in food allergy, and
- 3) The role of STAT5a and STAT5b in the function of regulatory T cells. Dr. Nadeau oversees a clinical research team that focuses on asthma and allergy clinical studies. She also focuses her efforts on collaborating and on mentoring others in the field of allergy and asthma.

Associate Professor Kari Nadeau's travel has been supported by ASCIA and the Centre for Food & Allergy Research (CFAR) www.foodallergyresearch.org.au

Associate Professor Wayne Shreffler, MD, PhD

Associate Professor of Pediatrics, Harvard Medical School

Division Chief, Pediatric Allergy and Immunology,

Director, Food Allergy Center, Principal Investigator, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital



Dr. Shreffler has developed a highly integrated research and clinical program to better understand the pathogenic mechanisms of food allergy and asthma and provide the best current and future care. The Shreffler laboratory focuses on the characterization of

cellular and humoral immune response to dietary antigens and the mechanisms of allergen-induced Th2 sensitization and oral tolerance. Areas of active investigation include the:

- 1) Mechanisms of allergenic dendritic cell (DC) activation by allergens and the DC signals that induce Th2 differentiation;
- 2) Role of regulatory T cells in natural and immunotherapy-induced oral tolerance;
- 3) Role of IgE diversity and basophil activation and their regulation in both the effector response and in adaptive immune deviation in the context of food allergy and asthma;
- 4) Relevance of humoral immunity in immunotherapy-induced oral tolerance.

The Food Allergy Center, led by Dr. Shreffler, is primarily focused on vaccine-like approaches and several phase I and II studies of oral immunotherapy for children and adults with food allergy that are active or in regulatory review stages. These interventional trials, one of which is funded by an AADCRC grant from the NIH together with Drs Andrew Luster, Uli von Andrian and Ramnik Xavier, are on the cutting edge of what is being offered for patients anywhere in the country.

Dr. Shreffler's experience conducting correlative mechanistic immunological studies in the context of such trials, together with the depth of expertise and resources at the Center for

International Keynote Speakers

Immunological and Inflammatory Diseases and MGH/Harvard Medical School, put the group in a unique position to make important new discoveries on how and why these therapies work for some individuals and what we can do to improve their efficacy.

Associate Professor Wayne Shreffler's travel has been supported by ASCIA and the Centre for Food & Allergy Research (CFAR) www.foodallergyresearch.org.au

Basten Orator

Professor James McCluskey, MBBS, MD, FAA, FRACP, FRCPA

Deputy Vice Chancellor Research, The University of Melbourne



Professor James McCluskey is Deputy Vice Chancellor Research (Head of Research) at The University of Melbourne, one of Australia's largest research organisations. His research career began as a medical student.

He worked in the All Africa Leprosy Rehabilitation and Training Center (now All Africa Leprosy, Tuberculosis and Rehabilitation Training Centre; ALERT) in Addis Ababa, Ethiopia. He then trained in Perth, Western Australia (WA) as a physician, working briefly as a Flying Doctor in the WA Kimberly region. He studied for four years at the National Institutes of Health (NIH) in the USA, then worked at Monash University, training in pathology until 1991, when he took a conjoint position with Flinders University and the Australian Red Cross Blood Service in Adelaide, South Australia. From 1997-2010 he was Chair in Microbiology and Immunology at The University of Melbourne, alternating as Head or Deputy Head of Department over this period, during which he built the strongest department of its kind in Australia.

Professor McCluskey has published more than 290 scientific articles on how genes control immunity, mechanisms of autoimmune disease, immune recognition and the basis of transplantation matching. He was awarded the Parr Prize from the Australian Rheumatism Association (ARA), the Priscilla Kincaid Smith Oration and medal of the Royal Australasian College of Physicians (RACP), the Rose Payne Award from the American Society for Histocompatibility and Immunogenetics (ASHI), the Ceppellini award from the

European Federation for Immunogenetics, the International Roche Organ Transplantation Fund Recognition Prize for Excellence in Organ Transplantation Research (jointly with Jamie Rossjohn), an Australian Museum Eureka award for scientific Research (McCluskey, Kjer-Nielsen and Rosjohn) and NHMRC Research Excellence Award for top NHMRC Program Grant in 2012. In 2010 he was elected to the Faculty of Science, Royal College of Pathologists Australasia (RCPA). He is a Fellow of the Australian Academy of Science (AA), RACP and RCPA.

Professor McCluskey has consulted for the Australian Red Cross Blood Service for more than 20 years, in South Australia, Victoria and New South Wales. He is Editor-in-Chief of the international immunogenetics journal *Tissue Antigens* and former President of the Australasian Society for Immunology (ASI), the Australasian and South East Asian Tissue Typing Society and International Histocompatibility Workshop Group. He has served on the board of directors of many of the most acclaimed medical research institutes in Australia including the Walter and Eliza Hall Medical Research Institute, Florey Neurosciences Institutes, Bionics Institute, St Vincent's Institute, the Burnet Institute and several Cooperative Research Centres. He led the development of the Peter Doherty Institute for Infection and Immunity, a \$210M project that brings together researchers, infectious disease physicians and public health laboratories in a new University institute, resembling the Centre for Disease Control and Prevention in the USA.

Invited Speakers – Australasia

Prof	Katie	Allen	VIC
A/Prof	Rohan	Ameratunga	NZ
Dr	Priscilla	Auyeung	VIC
Dr	Sara	Barnes	VIC
Ms	Kathy	Beck	QLD
Ms	Nadine	Bertali	VIC
Dr	Vanessa	Bryant	VIC
Prof	Dianne	Campbell	NSW
Dr	Sharon	Choo	VIC
Dr	Theresa	Cole	VIC
Prof	Matthew	Cook	ACT
Dr	Janet	Davies	QLD
Ms	Noelene	Davies	SA
Prof	Shyamali	Dharmage	VIC
Prof	Jo	Douglass	VIC
A/Prof	David	Fulcher	NSW
Dr	Pravin	Hissaria	SA
A/Prof	Robert	Heddle	SA
Ms	Olivia	Keene	VIC
Ms	Susan	Lester	NZ
A/Prof	Richard	Loh	WA
Dr	Seth	Masters	VIC
Prof	James	McCluskey	VIC
Ms	Vicki	McWilliam	VIC
Dr	Sam	Mehr	NSW
Ms	Merryn	Netting	SA
Prof	Robyn	O'Hehir	VIC
Dr	Jane	Peake	QLD
Prof	Susan	Prescott	WA
Ms	Anna	Richards	NZ
Ms	Ingrid	Roche	WA
Ms	Maria	Said	NSW
Dr	Joanne	Smart	VIC
Dr	William	Smith	SA
Ms	Simone	Stephens	NZ
A/Prof	Stuart	Tangye	NSW
Ms	Leone	Thiele	VIC
Dr	Jason	Tye-Din	VIC
Ms	Louise	Wienholt	NSW
Ms	Anastasia	Wilson	ACT
Dr	Melanie	Wong	NSW

Chairs

Prof	Katie	Allen	VIC
Dr	Priscilla	Auyeung	VIC
Dr	Sara	Barnes	VIC
Dr	Karl	Baumgart	NSW
Ms	Jan	Belcher	NSW
Dr	Julian	Bosco	VIC
Dr	Maia	Brewerton	VIC
Dr	Shannon	Brothers	NZ
Prof	Dianne	Campbell	NSW
Dr	Sharon	Choo	VIC
Ms	Christine	Collins	VIC
Prof	Matthew	Cook	ACT
Ms	Helen	Czech	VIC
Prof	Jo	Douglass	VIC
Dr	Marianne	Empson	NZ
Ms	Rebecca	Gibson	VIC
Ms	Pam	Hudson	SA
Dr	Tiffany	Hughes	SA
Prof	Connie	Katellaris	NSW
Ms	Nina	Kingon	NSW
A/Prof	Richard	Loh	WA
Dr	Jeremy	McComish	VIC
Dr	Andrew	McLean-Tooke	WA
Ms	Vicki	McWilliam	VIC
Dr	Sam	Mehr	NSW
Ms	Marry	Moussa	NSW
Dr	Raymond	Mullins	ACT
Dr	Katherine	Nicholls	VIC
Prof	Robyn	O'Hehir	VIC
Dr	Michael	O'Sullivan	WA
Dr	Jane	Peake	QLD
Ms	Ingrid	Roche	WA
Dr	Jan	Sinclair	NZ
Dr	Joanne	Smart	VIC
Dr	Graham	Solley	QLD
A/Prof	Rob	Stirling	VIC
Ms	Wendy	Stuart-Smith	NSW
Prof	Mimi	Tang	VIC
A/Prof	Stuart	Tangye	NSW
Dr	Dean	Tey	VIC
Ms	Leone	Thiele	VIC
Ms	Louise	Wienholt	NSW
Dr	Melanie	Wong	NSW

Information (A-Z)

Abstracts

Abstracts are published in the online Internal Medicine Journal (IMJ) for:

- ASCIA 2014 Annual Conference posters (displayed from 10-12 September)
- ASCIA 2014 Allergy and Immunology Update posters (displayed on 13 September)
- ASCIA 2014 Immunopathology Update posters (displayed on 13 September)
- ASCIA 2014 Clinical Grand Rounds (CGR) oral presentations by advanced trainees

The published abstracts can be accessed via the ASCIA website:

www.allergy.org.au/conferences/ascia-annual-conference/published-abstracts-ascia

Attendance Certificates

Certificates of attendance are provided to delegates in the registration envelope, together with a receipt for the registration payment.

Attractions

Visitors will find Melbourne an exciting city to explore. Modern architecture and design is juxtaposed with heritage buildings reflecting Australia's cultural history. But beneath the city's impressive façade, lies the true heart and soul of the city; laneways which snake the city grid to reveal cafes and bars, fashion houses, boutiques, innovative cuisine, galleries, theatres and museums.

Host City

Melbourne, located on the east coast, is the second largest city in Australia. More than 3.5 million people live in the city, which has been voted The World's Most Liveable City on a number of occasions. Melbourne has a lively passion for social eating and drinking, which is reflected in the thousands of restaurants serving up gastronomic experiences from around the world. Everywhere you will uncover a vast array of fashionable cafes, where you can enjoy Melbourne's existential coffee and cafe culture to the fullest.

Restaurants

Melbourne is a multi-cultural city and a wide range of cuisine is available throughout its many restaurants.

Shopping

Most shops in Melbourne are generally open from 0900 to 1700, Saturday to Wednesday and 0900 to 2100 Thursday to

Friday. In all stores and shopping centres major credit cards are accepted and tax-free shopping is possible within the city. Walking is the best way to shop, especially along Melbourne's arcades and laneways. Outside the city centre, visit shopping precincts like Chapel Street in South Yarra, Acland Street in St Kilda and Brunswick Street in Fitzroy, especially on weekends. Here you'll find everything from retro home wares to funky shops selling cult-in-the-making jewellery. These strips also have many street cafes. Travelling between Melbourne's suburbs is best done by tram.

Awards and Travel Scholarships

In 2014 a total of 18 Travel Scholarships of \$500 each have been awarded to Advanced Trainees who have submitted a poster and/or CGR abstract.

These travel scholarships are supported by educational grants from **CSL Behring, Shire, Takeda** and **ASCIA**.

In 2014 a total of 14 awards of \$1,000-\$1,500 each will be presented at the end of the conference for posters and CGR presentations, supported by educational grants from **Stallergenes, ASCIA, MEDA, Takeda, CSL Behring, National Asthma Council, Nestlé Nutrition** and **Shire**.

These awards will be listed on the ASCIA website after the ASCIA 2014 conference:

www.allergy.org.au/health-professionals/awards-grants/ascia-award-grant-scholarship-recipients

Climate

September is the first month of spring, which is the most changeable season of the year. A full range of weather may be experienced within a few days, from warm, calm and sunny to cold, windy and showery. There are several cloudy to overcast days. September is generally a windy month. Most strong winds are from the north, these often occur on the warmer days. There also are occasionally strong cold southwest winds with showery weather. The temperature usually reaches the mid-20s and nights are cool. The lowest temperature for the month in the city is 4°C. There are days with only a little drizzle or a light shower but heavy rain falls occasionally.

Disclaimers

In the event of industrial disruption or a natural disaster the conference organisers cannot be held responsible for any losses incurred by delegates. The program is correct at the time of printing; however the organisers reserve the right to alter the program if necessary.

Dress Code

The dress code is smart casual throughout the conference and cocktail for the Gala Dinner.

Exhibition

We encourage delegates to visit the ASCIA 2014 conference exhibition stands throughout the meeting.

All lunches and tea breaks will be served in the exhibition areas.

Smoke Free Policy

It is the policy that the ASCIA 2014 conference is smoke-free, including all related social functions.

Social Program

ASCIA 2014 Conference Welcome Function

Wednesday 10th September, 17.30 to 18.30, Melbourne Convention Centre (in the foyer adjacent to Melbourne Rooms 1 and 2)

ASCIA 2014 Conference Gala Dinner

Thursday 11th September, 18.30 to 23.30, Melbourne Aquarium

ASCIA 2014 Conference Closing Function / Wine and Cheese including award presentations

Friday 12th September, 17.30-18.30, Melbourne Convention Centre (in the foyer adjacent to Melbourne Rooms 1 and 2)

Concurrent sponsored dinners

Friday 13th September, 19.00, Melbourne Convention Centre

Advanced Trainee and Supervisors Dinner – organised and supported by CSL Behring

Nurses Dinner - organised and supported by Stallergenes

Wine and Cheese: ASCIA 2014 Immunopathology Update; ASCIA 2014 Allergy/Immunology Update.

Saturday 13th September, 17.00-18.00, Melbourne Convention Centre (in the foyer adjacent to Meeting Rooms 203, 204 and 205)

Special Requirements

Please provide details of any special diet, special needs or disability assistance required when you register.

Travel

Melbourne's public transportation system consists of trains, trams and buses as well as taxis.

Myki is Melbourne's ticket to travel on the city's trains, trams and buses. International and interstate visitors coming to Victoria can buy a full fare or concession Myki Visitor Pack from the Melbourne Visitor Centre at Federation Square or from the PTV Hub at Southern Cross Station.

For more information please visit

<http://ptv.vic.gov.au/getting-around/visiting-melbourne/>.



EPIPEN®

EPIPEN® Jr

(Adrenaline) Auto-Injectors 0.3/0.15mg

20+
YEARS⁵

NO.1 PRESCRIBED
ADRENALINE AUTO-INJECTOR⁶

LIFE HAPPENS
Be prepared.

**Being prepared means
having a plan to:**

- Recognise anaphylaxis risk in your susceptible patients¹
- Complete an ASCIA Anaphylaxis Action Plan for your patient²
- Prescribe 2x EpiPen® Adrenaline Auto-Injectors³
- Demonstrate injecting with an EpiPen® trainer pen
- Tell your patients about EpiClub® support⁴
- Make a yearly follow-up appointment to re-assess their allergy¹

PBS Information: Authority Required. Refer to PBS Schedule for full authority information.

BEFORE PRESCRIBING, PLEASE REVIEW APPROVED PRODUCT INFORMATION
AVAILABLE ON REQUEST FROM ALPHAPHARM.

MINIMUM PRODUCT INFORMATION EpiPen® Adrenaline Auto-Injector 0.3mg / 0.3mL EpiPen® Jr. Adrenaline Auto-Injector 0.15mg / 0.3mL. The following are not a complete listing. **Indication:** For the emergency treatment of anaphylaxis (acute severe allergic reaction) due to insect stings or bites, foods, drugs or other allergens. **Contraindications: Contraindications are relative, as this product is intended for use in life-threatening emergencies.** Certain arrhythmias, cerebral arteriosclerosis, vasopressor drug contraindication, shock (except anaphylactic shock), certain types of general anaesthesia. **Precautions:** Sulfite allergy, intravenous administration, ventricular fibrillation, prebrillatory rhythm, tachycardia, myocardial infarction, cardiovascular disease, organic heart disease, cardiac dilation, cerebral arteriosclerosis, prostatic hypertrophy, elderly, individuals with diabetes, hypertension, narrow angle glaucoma, hyperthyroidism, organic brain damage, psychoneurosis, phenothiazine-induced circulatory collapse, Parkinsonism. Avoid injection into hands, feet, ears, nose, buttocks, genitalia. Use in Pregnancy: Pregnancy Category A. Excreted in breast milk. Use with caution when maternal blood pressure is in excess of 130/80. Interactions: CNS medicines, alpha and beta adrenergic blockers, some general anaesthetics, hypoglycaemic agents. **Adverse Effects:** Anxiety, restlessness, tachycardia, respiratory difficulty, tremor, weakness, dizziness, headache, dyspnoea, cold extremities, pallor, sweating, nausea, vomiting, sleeplessness, hallucinations, flushing of face and skin. Psychomotor agitation, disorientation, impaired memory, potentially fatal ventricular arrhythmias, severe hypertension which may lead to cerebral haemorrhage and pulmonary oedema. Angina may occur in patients with CAD. **Dosage:** Single intramuscular injection into anterolateral aspect of thigh, repeat as directed if symptoms recur or have not subsided. Adults > 30kg: EpiPen® Auto-Injector [0.3mg adrenaline] Children 15–30kg: EpiPen® Jr. Auto-Injector [0.15mg adrenaline]. The prescribing physician may choose to prescribe more or less than this amount; please refer to relevant guidelines.

References: **1.** ASCIA: Guidelines for Adrenaline Autoinjector Prescription 2012. Available at http://www.allergy.org.au/images/stories/anaphylaxis/2012/ASCIA_Guidelines_adrenaline_autoinjector_script_2012.pdf accessed July 2014. **2.** ASCIA Action Plan for Anaphylaxis. Available at <http://www.allergy.org.au/health-professionals/anaphylaxis-resources/ascia-action-plan-for-anaphylaxis> accessed July 2014. **3.** Pharmaceutical Benefits Scheme. Adrenaline Auto-Injectors. Available at www.pbs.gov.au/medicine/item/8697R accessed July 2014. **4.** EpiClub®, www.epiclub.com.au accessed July 2014. **5.** Australian Register of Therapeutic Goods (ARTG) EpiPen® and EpiPen® Jr registration, 20/08/1993. Available at <https://www.ebs.tga.gov.au/> accessed July 2014. **6.** Pharmaceutical Benefits Schedule Item reports, August 1993 – June 2014. https://www.medicareaustralia.gov.au/statistics/pbs_item.shtml. EpiPen® is a registered trademark of Mylan, Inc. EpiPen® and EpiPen® Jr. are distributed in Australia by Alphapharm Pty. Limited. ABN 93 002 359 739, Level 1, 30 The Bond, 30–34 Hickson Road, Millers Point, NSW, 2000. Medical Information Phone: 1800 028 365, www.alphapharm.com.au inCeptiv ALP0538 August 2014

All about Freedom



gammanorm®

Human Normal Immunoglobulin
(165 mg/mL) For Subcutaneous Infusion

Subcutaneous home therapy with
3 years shelf life at 2-8°C, or
2 months at room temperature ($\leq 25^{\circ}\text{C}$)¹

PLEASE REVIEW PRODUCT INFORMATION BEFORE PRESCRIBING.

The approved Product Information is available at www.octapharma.com.au

MINIMUM PRODUCT INFORMATION: GAMMANORM® (Human Normal immunoglobulin, 165mg/mL). **INDICATIONS:** Replacement therapy; in adults and children with primary immunodeficiency (PID) syndromes and in myeloma or chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections. **CONTRAINDICATIONS:** (1) Hypersensitivity to homologous immunoglobulins (Ig) (i.e. very rare cases of IgA deficiency, when there are antibodies against IgA, (2) History of allergic reaction to human Ig preparations or hypersensitivity to constituents of the product. Gammanorm® must not be administered intramuscularly (i.m.) in cases of severe thrombocytopenia and disorders of haemostasis. **PRECAUTIONS:** Gammanorm® is made from human plasma which may contain infectious agents such as viruses and theoretically Creutzfeldt-Jacob Disease agents. Measures to reduce the risk of infections from plasma-derived products include; screening donors and donations, and inclusion of manufacturing steps to inactivate/remove viruses. Gammanorm® does NOT protect against HAV. Gammanorm® must not be administered intravenously as patients could develop shock. For a full list of precautions and risk factors refer to the approved PI. **ADVERSE REACTIONS:** Common (>1% - <10%): injection site reaction. Rare (>0.01% and <0.1%): hypersensitivity and hypotension. Very rare (<0.01%): headache, dizziness, nausea, vomiting, back pain, arthralgia, pyrexia, rigors, fatigue and anaphylactic shock. **OVERDOSE:** Consequences of an overdose are unknown. **DOSAGE & ADMINISTRATION:** gammanorm® should be administered via the subcutaneous (s.c.) or i.m. route. In exceptional cases, where s.c. administration may not be applicable, low doses of gammanorm® can be administered via the i.m. route. A loading dose of at least 0.2-0.5 g/kg may be required. After steady state IgG levels have been attained, maintenance doses are administered at repeated intervals to reach a cumulative monthly dose of the order of 0.4-0.8 g/kg. **S.C. infusion for home treatment:** should be initiated by a physician experienced in the guidance of home treatment. **S.C. infusion with pump:** a common dose is 0.6 mL (100 mg) gammanorm® per kg bodyweight once a week. Initial infusion rate: 10 mL/hour/pump. Infusion rate may be gradually increased by 1 mL/hour/pump every 3 to 4 weeks. The maximum dose administered is 40 mL/hour using two pumps simultaneously. **I.M. injection:** must be given by a physician or nurse. **Paediatric Patients:** maintenance doses of about 80 to 100 mg/kg/week are usually administered to reach a cumulative monthly dose of the order of 0.4-0.8 g/kg. **STORAGE CONDITIONS:** Shelf life is 3 years, store at 2°C to 8°C (Refrigerate. Do not freeze). Protect from light. Do not use after expiry date. Product may be stored below 25°C for a single period of 2 months - the product expires at the end of the 2-month period. The date of removal from refrigeration and the new expiry date must be noted on the outer carton. Based on gammanorm® Product Information, Date of Approval 28 March 2013.

PBS Information: This product is not listed on the PBS. gammanorm® is funded under arrangements established by the National Blood Authority. Please refer to the National Blood Authority for details.

References: 1. gammanorm® approved Product Information, Octapharma, 28 March 2013

gammanorm® is a registered trademark of Octapharma® AG.

Octapharma® Australia Pty Ltd
ABN: 23 109 574 692
Jones Bay Wharf
42/26-32 Pirrama Road
Pyrmont NSW 2009

Tel: 02 8572 5800
Fax: 02 8572 5890
Medical Enquiries: 1800 780 169
Email: aumedinfo@octapharma.com
www.octapharma.com.au

octapharma®

For the safe and optimal use of human proteins

Date of Preparation: July 2014

**I AM FIGHTING
MY ALLERGY**

**I WANT TO LIVE
LIKE EVERYONE ELSE**

Stallergenes is a global allergy company, driven by a patient centric approach, that provides allergy patients with innovative, targeted and long-term solutions.

INNOVATION AT HAND
PATIENTS AT HEART



STALLERGENES



Powerful 24hr allergic rhinitis relief^{1,2}

 **omnaris**[®]
Once a day

Nasal Spray (ciclesonide 50 mcg)

PBS Information: This product is not listed on the PBS.

Before prescribing, please review approved Product Information available from Takeda Pharmaceuticals.
For the most up-to date Product Information, call 1800 675 957.

MINIMUM PRODUCT INFORMATION OMNARIS[®] NASAL SPRAY. INDICATIONS: Treatment of seasonal allergic rhinitis in adults and children 6 years of age and older. Treatment of perennial allergic rhinitis in adults and adolescents 12 years of age and older. **DOSAGE AND ADMINISTRATION:** OMNARIS should only be administered by the intranasal route. The recommended dose is 200 µg per day administered as 2 actuations (50 µg/actuation) in each nostril once daily. The maximum total daily dosage should not exceed 200 µg/day. Prior to initial use, shake gently and then prime the pump by actuating 8 times. If not used for 4 or more consecutive days, shake gently and reprime with 1 actuation or until a fine mist appears. Advise users to tilt the head forward slightly, keep the bottle upright, press the pump quickly and firmly and inhale through the nose as they spray. **CONTRAINDICATIONS:** Known hypersensitivity to any of the ingredients. **PRECAUTIONS:** Rarely, immediate hypersensitivity reactions or contact dermatitis may occur after the administration of intranasal corticosteroids. Patients with a known hypersensitivity reaction to other corticosteroid preparations. Patients who are using drugs that suppress the immune system. Chickenpox and measles. Recent nasal septal ulcers, nasal surgery, or nasal trauma. Examine nasal mucosa periodically. Patients with active or quiescent tuberculosis infections of the respiratory tract or in patients with untreated local or systemic fungal or bacterial infections; systemic viral or parasitic infections; or ocular herpes simplex. Rare instances of wheezing, nasal septum perforation, cataracts, glaucoma, and increased intraocular pressure have been reported following the intranasal application of corticosteroids. Change in vision. Patients with a history of glaucoma and/or cataracts. Physicians should closely follow the growth of children and adolescents taking corticosteroids by any route. Larger than recommended doses should be avoided. Patients transferred from systemic corticosteroids should be carefully monitored for acute adrenal insufficiency in response to stress. Rapid decreases in systemic corticosteroid dosages may cause a severe exacerbation of symptoms. Greater sensitivity of some older individuals cannot be ruled out. Pregnancy Category B3. Interactions: potent inhibitors of CYP 3A4 (e.g. ketoconazole, protease inhibitors for the treatment of HIV infections). **ADVERSE EFFECTS:** Adult and Adolescents: Common adverse events: Headache, epistaxis, nasopharyngitis, nasal discomfort, ear pain. Children: headache, nasopharyngitis, pharyngolaryngeal pain. Post-marketing Experience: Hypersensitivity reactions, including angioedema, loss of consciousness, nasal oedema, and dyspnoea. Please review full Product Information before prescribing. Date of Preparation: 15 February 2013. Based on Full PI with TGA date of last amendment 21 January 2013. **REFERENCES:** 1. Ratner PH *et al.* *J Allergy Clin Immunol* 2006; 118(5): 1142–8. 2. Meltzer EO *et al.* *Ann Allergy Asthma Immunol* 2007; 98(2): 175–81. Takeda Pharmaceuticals Australia Pty Ltd, Ground Floor, 2-4 Lyonpark Road, Macquarie Park NSW 2113. Phone 1800 675 957. Omnaris and logo are registered trademarks of Takeda GmbH. AUS/OMN/14/0068. TAOM8791. July 2014.



Clinical Grand Rounds: Program

Wednesday 10 September 2014, 15.30-17.30

CRG No.	Presentation Schedule	First Name	Last Name	Title of presentation
1	15.30-15.38	Anthea	Anantharajah	THE MAN WITH THE DRAGON TATTOO
2	15.38-15.46	Jack	Bourke	AUTOSOMAL RECESSIVE TRANSMISSION OF A NOVEL TNFRSF1A MUTATION IN TUMOUR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC FEVER SYNDROME
3	15.46-15.54	Jason (Jie Shen)	Fok	TALE OF A HINDU PRIEST
4	15.54-16.02	Lara	Ford	CHRONIC GRANULOMATOUS DISEASE: A TWIST IN THE TAIL
5	16.02-16.10	Jovanka	King	AN OXYMORONIC HYPERSENSITIVITY REACTION TO CIPROFLOXACIN
6	16.10-16.18	Monique	Lee	SLE UNEXPECTEDLY COMPLEMENTED BY A DENSER DIAGNOSIS
7	16.18-16.26	Eton	Lin	ANGIOEDEMA AND LOW C1 ESTERASE INHIBITOR FUNCTION DURING PREGNANCY
8	16.26-16.34	Karen	Lindsay	FAMILIAL CHILBLAIN LUPUS, A FAMILY OF FOUR
9	16.34-16.42	Paxton	Loke	A RAG OF A JOURNEY: A CASE OF UNCONDITIONED HSCT FOR SCID
10	16.42-16.50	Claire	Nickolls	A LATE DIAGNOSIS OF X-LINKED SEVERE COMBINED IMMUNODEFICIENCY
11	16.50-16.58	Stephanie	Richards	PURINE NUCLEOSIDE PHOSPHORYLASE (PNP) DEFICIENCY
12	16.58-17.06	Sarah	Sasson	MONOCLONAL B-CELL POPULATION OF INDETERMINANT MALIGNANT POTENTIAL IN THE SETTING OF ATYPICAL CVID ASSOCIATED WITH LYMPHADENOPATHY AND SPLENOMEGALY
13	17.06-17.14	Jody	Tansy	A CASE OF OMALIZUMAB-ASSOCIATED ANAPHYLAXIS
14	17.14-17.22	Hui Wen	Tee	PINNING DOWN THE CAUSE: AN UNUSUAL CASE OF CHRONIC EOSINOPHILIA
15	17.22-17.30	Grace	Thompson	IPEX SYNDROME NOT JUST A PAEDIATRIC CONDITION

Poster Abstracts: Index

Please note:

- Poster numbers in this list correspond to the numbers published in the Internal Medicine Journal (IMJ)
- Posters will also be allocated a display number which corresponds to an allotted poster round session
- Presenting authors need to check the poster boards for their poster location and must be present with their poster at the time of their allotted poster round session
- CONF = Annual Conference, IPU = Immunopathology Update, AIU = Allergy and Immunology Update

1	Amir Abdul Latiff	ASSESSING ALLERGY RISK AMONG MALAYSIAN CHILDREN: A NATIONWIDE CROSS SECTIONAL STUDY	CONF POSTER
2	Nayyar Ahmed	DISCOVERING THE EFFECTS OF OMEGA-3 AND OMEGA-6 FATTY ACIDS ON ALLERGY USING A HEK-BLUE CELL LINE	IPU POSTER
3	Fahad Aldakheel	TOTAL NITROGEN PRODUCTS (NO _x) IN THE EXHALED BREATH CONDENSATE OF ADOLESCENTS WITH ASTHMA	AIU + CONF POSTER
4	Shatha Alduraywish	FOOD SENSITISATION: FROM BIRTH TO 18 YEARS: A LONGITUDINAL ANALYSIS OF A COHORT AT RISK OF ALLERGIC DISEASE	AIU + CONF POSTER
5	Ulus Atasoy	RNA-BINDING PROTEIN HUR REGULATES CD4+ TH2 DIFFERENTIATION AND IL-2 HOMEOSTASIS AND IS REQUIRED FOR ONSET OF ALLERGIC AIRWAY INFLAMMATION	CONF POSTER
6	Karen Best	EFFECT OF MATERNAL DIETARY LONG CHAIN POLYUNSATURATED FATTY ACID INTAKE DURING PREGNANCY ON CLINICAL OUTCOMES OF ALLERGIC DISEASE IN THE OFFSPRING: A SYSTEMATIC REVIEW	CONF POSTER
7	Annaliese Blincoe	MANAGEMENT DILEMMAS IN WISKOTT-ALDRICH SYNDROME	CONF POSTER
8	Claudine Bonder	EPICUTANEOUS APPLICATION OF FINGOLIMOD ATTENUATES ALLERGIC INFLAMMATION	CONF POSTER
9	Gayan Bowatte	THE INFLUENCE OF EARLY LIFE TRAFFIC RELATED AIR POLLUTION EXPOSURE ON ASTHMA, ALLERGY AND SENSITIZATION: A SYSTEMATIC REVIEW AND A META-ANALYSIS OF BIRTH COHORT STUDIES	CONF POSTER
10	Andrew Broadfoot	DENSE FINE SPECKLED IMMUNOFLUORESCENCE PATTERN IN AN AUSTRALIAN POPULATION	IPU POSTER
11	Christine Bundell	ANTIMITOCHONDIAL ANTIBODY TESTING IN THE CLINICAL LABORATORY: PRACTICAL AND CLINICAL CONSIDERATIONS	IPU POSTER
12	Christine Bundell	COMPLEMENT TESTING - THE LONG OR SHORT APPROACH	IPU POSTER
13	Christine Bundell	ENA CHARACTERISATION - ANALYSIS OF 7 YEARS OF TESTING	IPU POSTER
14	Dianne Campbell	ADHERENCE TO EXTENSIVELY HEATED EGG AND COW'S MILK FOLLOWING SUCCESSFUL ORAL FOOD CHALLENGE	CONF POSTER
15	Dianne Campbell	RARE STAT1 GOF MUTATION IN DNA BINDING DOMAIN CAUSING MILD CMC	CONF POSTER
16	Janice Capstick	CHARACTERISTICS OF AUCKLAND CITY HOSPITAL IMMUNOLOGY DAY WARD USE	CONF POSTER
17	Josh Chatelier	IMPROVING TREATMENT DELIVERY IN IMMUNOGLOBULIN DEFICIENCY: A QUALITY IMPROVEMENT SURVEY	AIU + CONF POSTER

Poster Abstracts: Index

18	Gary Chew	TNFRSF13B VARIANTS IN SYSTEMIC LUPUS ERYTHEMATOSUS AND PRIMARY ANTIBODY DEFICIENCY	CONF POSTER
19	Jeremy Chou	CLINICAL OUTCOMES OF PATIENTS WITH DUAL POSITIVITY FOR PROTEINASE 3 AND MYELOPEROXIDASE SPECIFIC ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES	IPU + CONF POSTER
20	Terri Corderoy	CLINICAL OBSERVATIONS OF BAKED MILK FOOD CHALLENGES IN COW'S MILK ALLERGIC CHILDREN	AIU + CONF POSTER
21	Ahmed Daoud	A PROSPECTIVE CLINICAL STUDY EVALUATING THE ROLE OF COLCHICINE OR VITAMIN E IN COMBINATION WITH PRAZQUANTEL IN TREATMENT OF HUMAN S. MANSONI	IPU POSTER
22	Ahmed Daoud	EXPERIMENTAL HETEROPHYIASIS: HISTOPATHOLOGICAL AND IMMUNOLOGICAL STUDY	IPU + CONF POSTER
23	Grace Isobel Davies	SUCCESSFUL DESENSITISATION TO DEFERASIROX IN A PAEDIATRIC THALASSAEMIA PATIENT: A CASE REPORT	IPU + CONF POSTER
24	Renee Deleuil	ANAPHYLAXIS: A NURSING EDUCATION EMERGENCY	AIU + CONF POSTER
25	Diogenes Ferreira	AIRWAY REMODELING DIFFERENTIATES ALLERGIC FROM NONALLERGIC SEVERE ASTHMA	CONF POSTER
26	Jason (Jie Shen) Fok	TREATING HONEY BEE VENOM IN MASTOCYTOSIS - OUR EXPERIENCE IN ADELAIDE	CONF POSTER
27	Jason (Jie Shen) Fok	UNDERSTANDING ADVERSE DRUG REACTIONS AND THEIR IMPLICATIONS AMONGST HEALTH PROFESSIONALS	CONF POSTER
28	Caroline Foreman	ANAPHYLAXIS TO INTERNET-PURCHASED SIDENAFIL	CONF POSTER
29	Caroline Foreman	DEVIC'S DISEASE WITH A PANOPLY OF AUTOANTIBODIES	CONF POSTER
30	Alma Fulurija	HELICOBACTER PYLORI IMMUNOTHERAPY PROTECTS MICE FROM THE DEVELOPMENT OF ALLERGIC ASTHMA	AIU + CONF POSTER
31	Philip George	VOLTAGE GATED POTASSIUM CHANNEL ANTIBODIES AND THE AWAKENING	CONF POSTER
32	Paul Gray	A SUCCESSFUL APPLICATION OF NEXT GENERATION SEQUENCING TO THE DIAGNOSIS OF ADAPTIVE PRIMARY IMMUNODEFICIENCY	CONF POSTER
33	Robert Heddle	A CONTROLLED STUDY OF DELTA INULIN ADJUVANTED HONEY BEE VENOM	AIU + CONF POSTER
34	Kuang-Chih Hsiao	SAFETY OF PAEDIATRIC ORAL FOOD CHALLENGES IN A TERTIARY PRIVATE HOSPITAL	AIU + CONF POSTER
35	Sandip Kamath	A COMPARATIVE ANALYSIS OF SERUM IGE ANTIBODIES SPECIFIC TO THE MAJOR ALLERGEN TROPOMYOSIN IN PRAWN ALLERGIC ADULTS AND CHILDREN, USING A NOVEL IMMUNO-PCR BASED STRATEGY	CONF POSTER
36	Narinder Kaur	ACQUISITION OF KNOWLEDGE AND SKILLS AFTER 'ANAPHYLAXIS EDUCATION' IN A REGIONAL CENTRE TO IMPROVE PATIENT CARE	CONF POSTER
37	Sonia Kaushik	LUNG FUNCTION DECLINE IN MEN AND WOMEN PARTICIPATING IN THE EUROPEAN COMMUNITY RESPIRATORY HEALTH SURVEY (ECRHS) IN AUSTRALIA	CONF POSTER


38	Philippa Kirkpatrick	INTRAVENOUS IMMUNOGLOBULIN USE IN AUSTRALIA	CONF POSTER
39	Elizabeth Klinken	A CASE OF FUNCTIONAL NK CELL DEFICIENCY	CONF POSTER
40	Martina Koeberl	FOOD ALLERGEN QUANTIFICATION - MASS SPECTROMETRY AS ALTERNATIVE TO BIOLOGICAL METHODS	CONF POSTER
41	Melisa Lau	FARM EXPOSURE IN EARLY LIFE MODIFIES THE ASSOCIATION BETWEEN TLR6 POLYMORPHISMS ON ASTHMA	CONF POSTER
42	Alison Lee	WEANING PRACTICES AND FOOD ALLERGY OUTCOMES IN SINGAPORE	CONF POSTER
43	SenHong Lee	PREVALENCE OF FOOD SENSITIZATION AND IGE-MEDIATED FOOD ALLERGY IN INFANTS LESS THAN 12 MONTHS OF AGE PRESENTING WITH ATOPIC DERMATITIS	AIU + CONF POSTER
44	Jamma Li	GIVING HIS TWO SENSES TO THE DIAGNOSIS	CONF POSTER
45	Jamma Li	RESOLUTION OF AQUAPORIN-4 ANTIBODIES IN A PATIENT WITH NEUROMYELITIS OPTICA TREATED WITH HUMAN AUTOLOGOUS STEM CELL TRANSPLANT	CONF POSTER
46	Jamma Li	THE IMPORTANCE OF INDIRECT IMMUNOFLUORESCENCE IN THE DIAGNOSIS AND MANAGEMENT OF PARANEOPLASTIC PEMPHIGUS	IPU + CONF POSTER
47	Bahar Liravi	INTERLEUKIN-4 AND INTERLEUKIN-13 CELLULAR SOURCES IN THE SHEEP MODEL OF ASTHMA	IPU + CONF POSTER
48	Saul Oswaldo Lugo Reyes	MULTIVARIATE LOGISTIC REGRESSION AND LINEAR DISCRIMINANT ANALYSIS TO ASSIST THE CLINICAL DIAGNOSIS OF PRIMARY IMMUNODEFICIENCIES	IPU + CONF POSTER
49	Sam Mehr	CRYOPYRIN ASSOCIATED PERIODIC SYNDROMES: PREVALENCE, CLINICAL FEATURES, TREATMENT AND OUTCOMES IN AUSTRALIAN CHILDREN AND ADULTS	CONF POSTER
50	Sam Mehr	FPIES EPIDEMIOLOGY IN AUSTRALIA. RESULTS FROM A 2-YEAR PROSPECTIVE POPULATION STUDY	CONF POSTER
51	Sam Mehr	IMMUNE PHENOTYPE OF PATIENTS WITH CHARGE SYNDROME	CONF POSTER
52	Sam Mehr	SAFETY AND CLINICAL PREDICTORS OF REACTING TO EXTENSIVELY HEATED COW'S MILK CHALLENGE IN COW'S MILK-ALLERGIC CHILDREN: A PROSPECTIVE COHORT STUDY	CONF POSTER
53	Sam Mehr	SNAPSHOT OF PAEDIATRIC FOOD ALLERGY PRACTICES - SCREENING AND FOLLOWUP	CONF POSTER
54	Sam Mehr	TOLERANCE TO BOILED PEANUT IN PEANUT-ALLERGIC CHILDREN	CONF POSTER
55	Dhanya Menon	BREAST FEEDING ANAPHYLAXIS	CONF POSTER
56	Jessica Metcalfe	MULTIPLE EGG ALLERGENS ELICIT Th2 CYTOKINE RESPONSES THAT ARE ASSOCIATED WITH THE INCIDENCE OF EGG ALLERGY	CONF POSTER
57	Fiona Moghaddas	CABBAGE INDUCED ANAPHYLAXIS: A LESSON IN DIAGNOSIS	AIU + CONF POSTER
58	Fiona Moghaddas	INCIDENTAL DETECTION OF SP100 AND GP210 IN PATIENTS WITH NORMAL LIVER FUNCTION TESTS	IPU + CONF POSTER

Poster Abstracts: Index

59	Fiona Moghaddas	NEED FOR INTENSIVE CARE IN PATIENTS ADMITTED FOR ASTHMA: RED FLAGS FROM THE SOCIAL HISTORY	AIU + CONF POSTER
60	Kathryn Mulligan	OPEN FOOD CHALLENGES IN PRIVATE ROOMS: ARE THEY SAFE?	AIU + CONF POSTER
61	Raymond J Mullins	CHILDHOOD FOOD ALLERGY: ARE WE REACHING THE PEAK?	CONF POSTER
62	MaiAnh Nguyen	CYTOKINE RESPONSE IN A PATIENT RECEIVING ALEMTUZUMAB	IPU + CONF POSTER
63	Kevin O'Connor	THE SPECTRUM OF NEUROMYELITIS OPTICA AND THE ROLE OF AQUAPORIN-4 ANTIBODIES	IPU + CONF POSTER
64	Dwan Price	ALLERGEN-EPITHELIAL INTERACTIONS: IDENTIFYING EPITHELIAL ENDOCYTOTIC PATHWAYS OF PEANUT ALLERGENS	CONF POSTER
65	Naghmeh Radhakrishna	CASE OF ANAPHYLAXIS TO OATS AFTER SKIN SENSITIZATION	CONF POSTER
66	Naghmeh Radhakrishna	SETTING UP A DIFFICULT ASTHMA CLINICAL PROTOCOL USING VALIDATED QUESTIONNAIRES	CONF POSTER
67	Kristina Rueter	ACUTE RESPIRATORY DISTRESS SYNDROME AS A RARE PRESENTATION OF KAWASAKI DISEASE	CONF POSTER
68	Maria Said	AN INSIGHT INTO AFFECTED AUSTRALIAN PARENTS' LIVED EXPERIENCES WITH CHILDREN'S FOOD ALLERGY	CONF POSTER
69	Sandra Salter	PHARMACIST DEMONSTRATION OF ADRENALINE AUTOINJECTORS IS ACCURATE, BUT THERE IS ROOM FOR IMPROVEMENT	AIU + CONF POSTER
70	Sandra Salter	PHARMACISTS' RESPONSE TO ANAPHYLAXIS IN THE COMMUNITY (PRAC): A RANDOMISED, SIMULATED PATIENT STUDY OF PHARMACIST PRACTICE	AIU + CONF POSTER
71	Bella Shadur	EXERCISE-INDUCED ANAPHYLAXIS: A PAEDIATRIC CASE SERIES	CONF POSTER
72	Michael Sharp	DYNAMIC CROSS-REACTIVITY FROM MOLECULAR ANALYSIS OF FISH PARVALBUMINS MAY IMPROVE FISH ALLERGY MANAGEMENT	CONF POSTER
73	Mohammad Reza Sheikh Sajjadih	CYTOKINE STATUS IN UKRAINIAN CHILDREN WITH IRRITABLE BOWEL SYNDROME RESIDING IN A RADIOACTIVE CONTAMINATED AREA	IPU + CONF POSTER
74	Juan Stephen	FISH ALLERGY: UNDERSTANDING ALLERGEN DIVERSITY	CONF POSTER
75	Simone Stephens	EXPERIENCE OF TRANSFERRING FROM IVIG TO SCIG	AIU + CONF POSTER
76	Simone Stephens	SUBCUTANEOUS IMMUNOTHERAPY PRACTICE: WHY THE POSTERIOR OR LATERAL UPPER ARM?	AIU + CONF POSTER
77	Michael Stone	AUSTRALIAN GOVERNANCE AND MANAGEMENT FRAMEWORK FOR IMMUNOGLOBULIN PRODUCTS	CONF POSTER
78	Michael Sutherland	SEVERE REFRACTORY ALLERGIC ASTHMA IN AUSTRALIA: THE AUSTRALIAN XOLAIR REGISTRY (AXR)	CONF POSTER
79	Hui Wen Tee	ANAPHYLAXIS IN SUBCUTANEOUS IMMUNOTHERAPY FOR RESPIRATORY ALLERGIES - A LARGER SPECTRE THAN THE CURRENT EVIDENCE SUGGESTS?	CONF POSTER

80	Hui Wen Tee	NOT JUST YOUR GARDEN VARIETY CHRONIC URTICARIA STRONGYLOIDES IN CHRONIC URTICARIA: THE AUSTRALIAN CONTEXT	CONF POSTER
81	Hui Wen Tee	X-LINKED LYMPHOPROLIFERATIVE SYNDROME TYPE 2 DIAGNOSED IN A 20 YEAR-OLD MALE PRESENTING WITH HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS ON A BACKGROUND OF INFANTILE-ONSET CROHNS DISEASE	CONF POSTER
82	Yang Tran	ANAPHYLAXIS IN AN ADULT POPULATION: A CLINICAL AUDIT OF PRACTICE IN A LARGE AUSTRALIAN TERTIARY REFERRAL HOSPITAL	CONF POSTER
83	Margot Treloar	THE IMPLEMENTATION AND OUTCOMES OF MIXED TREE-NUT ORAL FOOD CHALLENGES IN A TERTIARY ALLERGY CLINIC SETTING	AIU + CONF POSTER
84	Briony Tyquin	A SNAPSHOT OF ANAPHYLAXIS TRAINING PROVIDED IN NSW SCHOOLS WITH STUDENTS DEEMED AT RISK OF ANAPHYLAXIS: 2009- 2014	AIU + CONF POSTER
85	Nicolas Urriola	ANAPHYLAXIS TO AMOXYCILLIN DUE TO ALLERGIC RESENSITISATION PROVOKED BY PRIOR NEGATIVE SKIN TEST AND CHALLENGE.	CONF POSTER
86	Sheryl Van Nunen	TICK REMOVAL TECHNIQUES PRACTISED BY TICK ANAPHYLAXIS SUFFERERS	CONF POSTER
87	Christopher Vidal	A POLYMORPHISM IN THE PSORIASIS SUSCEPTIBILITY 1 CANDIDATE 1 (PSORSIC1) GENE IS NOT IN LINKAGE WITH HLA-B*58:01 ALLELE IN AUSTRALIANS.	IPU + CONF POSTER
88	Christopher Vidal	DEVELOPMENT OF A RAPID TEST FOR HLA-B*5801/5701 FOR DETECTION OF GENETIC SUSCEPTIBLE INDIVIDUALS FOR DRUG INDUCED HYPERSENSITIVITY	IPU + CONF POSTER
89	Nilakshi Waidyatillake	THE EFFECT OF BREASTFEEDING ON LUNG FUNCTION AT 12 AND 18 YEARS IN A COHORT WITH A FAMILY HISTORY OF ALLERGY	AIU + CONF POSTER
90	Brynn Wainstein	REPEAT ORAL FOOD CHALLENGES IN PEANUT AND TREE NUT ALLERGIC CHILDREN WITH A HISTORY OF MILD / MODERATE REACTIONS.	CONF POSTER
91	Robert Wiedemann	IMPROVING PEAK EXPIRATORY FLOW MONITORING IN THE ACUTE CARE SETTING	CONF POSTER
92	Louise Wienholt	RECOMMENDATIONS FOR SERUM FREE LIGHT CHAINS (SFLC) MEASUREMENT IN ROUTINE LABORATORIES	IPU + CONF POSTER
93	Ray Wolf	COMPARISON OF NEEDLE PENETRATION DEPTH PROBABILITIES OF TWO EPINEPHRINE AUTO-INJECTORS	CONF POSTER
94	James Yun	FOOD-DEPENDENT EXERCISE-INDUCED ANAPHYLAXIS (FDEIA) DUE TO Gly m 6 IN SOY	CONF POSTER
95	James Yun	PATIENTS WITH POSITIVE BETA-LACTAM SKIN TESTS HAD ANAPHYLAXIS, HOSPITAL PRESENTATIONS AND/OR REACTIONS TO PARENTERAL BETA-LACTAMS	CONF POSTER
96	Celia Zubrinich	GOATS CHEESE ANAPHYLAXIS FOLLOWING CUTANEOUS SENSITISATION BY SKIN CARE PRODUCTS CONTAINING GOATS MILK: TWO CASES	CONF POSTER

Exhibition Floorplan



For The Main Conference (Wed –Fri):

- All exhibition stands will be located in Melbourne Room 1 on Level 2, adjacent to Melbourne Room 2, where the talks will be presented.
- The registration desk will be located in the foyer adjacent to Melbourne Rooms 1 and 2.

For The Saturday Meetings:

- The table top exhibitor displays will be located in the foyer adjacent to meeting rooms 203-205, where the talks will be presented.
- Exhibition stands on Saturday are not allocated stand numbers.
- The registration desk and catering (for lunch and tea breaks) will also be set up in the foyer.

Exhibitors

Stand No.	Exhibitor	Wed-Fri	Sat
14,15	Abacus-ALS	2	1
9	Abbott	1	
23	AIFA / ASCIA	1	
18	Allergend	1	1
10	Allergy & Anaphylaxis Australia	1	1
11	Allergy New Zealand	1	1
31,32	Alphapharm	2	1
8	AMSL/NZMS	1	
12	AusEE	1	1
13	Autoimmune Resource & Research Centre	1	1
37	Baxter Healthcare	1	
29,30	CSL Behring	2	1
	Diagnostic Solutions		1
7	Ego Pharmaceuticals	1	
25	ENT Technologies	1	
17	GSK	1	
19	HAE Australasia	1	1
20	IDFA	1	1
21	IDFNZ	1	1
3,4	Meda Pharmaceuticals	2	1
24	MSD	1	
38	Neilmed	1	
35,36	Nestlé	2	2
27,28	Novartis	2	
5	Danone Nutricia Early Life Nutrition	1	
6	Nutricia Advanced Medical	1	
16	Octapharma	1	1
33,34	Shire Australia	2	
1,2	Stallergenes	2	1
26	Takeda Pharmaceuticals	1	
22	TAMS	1	1
	Werfen		1
TOTAL		38	20

Exhibitor Directory



www.abacus-als.com

Abacus ALS will showcase a number of new advances in allergy, asthma and autoimmunity.

Kerstin Wall (Scientific Advisor, Thermo Fisher Scientific) will be available to discuss new developments in allergy testing. We are also focused on standardisation across sIgE testing in laboratories throughout Australia and New Zealand and will have updates in this area available for visitors to our stand.

The gastrointestinal disease test menu continues to grow on the Phadia® platforms and we are pleased to provide updates on our tests performance in this important area which assists in the diagnosis of those who suffer from IBD related diseases. New tests for the EliA range include a new revised assay for TG and TPO and various complementary tests in the diagnosis of ANA testing.

Abacus ALS will provide visitors to our booth a complimentary copy of the most up-to-date allergy and autoimmunity resources on a USB stick.



www.abbottnutrition.com.au

Abbott Nutrition, a division of Abbott Australasia is committed to advancing patient care by developing innovative solutions in nutritional products. Our leading-edge science is behind some of the world's most trusted names in medical nutrition, including EleCare®, which is a nutritionally complete amino acid based formula with 1/3 of fat as Medium Chain Triglycerides (MCTs), to aid fat absorption. This product has been specially formulated for infants and children who have multiple food allergies, including cow's milk protein allergy. In addition, EleCare Unflavoured and EleCare Vanilla are also indicated for the treatment of Eosinophilic Oesophagitis. EleCare® is PBS listed and is available in three variants, EleCare Unflavoured, EleCare Unflavoured with LCP and EleCare Vanilla.



allergy and immunology foundation of australasia

www.allergyimmunology.org.au

The Allergy and Immunology Foundation of Australia (AIFA) is dedicated to funding research into allergy and other immune diseases in Australia and New Zealand. This knowledge will lead to strategies for prevention, better treatments and potential cures.

Launched in 2013, AIFA is an initiative of the Australasian Society of Clinical Immunology and Allergy (ASCI), the peak professional body of immunology and allergy specialists in the region. ASCIA has identified the need and risen to the challenge of fundraising for the future.

Someone you know suffers from allergic disease. You can help. Donate at www.allergyimmunology.org.au



THE ULTIMATE DUST MITE PROTECTIVE BEDDING

www.allergend.com.au

AllergEnd Plus is proud to introduce our latest innovation – The new AllergEnd Plus EasyCare Fitted Sheet. The new fitted sheet alleviates the need to wash the full zip up mattress every 8-12 weeks.

The EasyCare fitted sheet is designed to go over our zip up mattress covers and under the normal linen fitted sheet. It stops dead skin, house dust mites and allergens from contacting the full zip up cover and when used together the zip up mattress covers only need washing annually. Made from the same barrier fabric as our zip up covers the EasyCare Fitted Sheet is 100% Oeko-Tex Standard 100 certified chemical free cotton, super breathable and luxurious to sleep on.



www.allergyfacts.org.au

Allergy & Anaphylaxis Australia (A&AA) is a national, non-profit, community support organisation established in 1993 to support and assist those affected by allergy and anaphylaxis.

Our aim is to improve the quality of life of those affected by allergy whilst minimising risk to their health and wellbeing.

The organisation:

- Advocates for people living with allergies when communicating with government, health and teaching professionals, food industry and the broader community; and
- Strives to raise awareness of allergy in the Australian community and provide evidence-based information, resources and services to support those with allergy and those who live with the risk of anaphylaxis.

Together with ASCIA, Allergy & Anaphylaxis Australia convened a national Allergy Summit in August 2014 and will continue to work with ASCIA to develop a National Allergy Strategy.

For more information on allergy and anaphylaxis see our website or call 1300 728 000.



www.allergy.org.nz

Allergy New Zealand is the national patient support organisation in New Zealand. With the support of a Medical Panel (all members of ASCIA) we work to raise awareness, provide evidence-based information and education on all allergies, and support through a national volunteer network to families with children with food allergy. Our quarterly magazine, Allergy Today, is distributed to over 5,000 health professionals.

We also represent the interests of the allergic population through submissions and participation in working groups; and are involved in research into the burden of food allergy in New Zealand.

See our website for more information: www.allergy.org.nz



www.alphapharm.com.au

There are 7 Billion Reasons why we do what we do.

7 years ago Alphapharm became a part of Mylan. As a part of the worldwide Mylan team, we're committed to innovating to meet unmet needs, and to providing the world's 7 billion people with access to high-quality medicines at competitive prices. We're also committed to providing support beyond the supply of pharmaceuticals.

Anaphylaxis, a life-threatening allergic reaction, is a significant public health problem. When anaphylaxis occurs, every

minute matters and immediate access to adrenaline and emergency medical care is crucial. We advocate for increased anaphylaxis awareness, preparedness and access to treatment, because even one anaphylactic episode without access to adrenaline is one too many.

Alphapharm's EpiPen® is the number one prescribed epinephrine auto-injector in Australia. Alphapharm supplies EpiPen® to Australians via the PBS, with two pens available on each prescription.



www.ausee.org

ausEE Inc. is an Australian charity dedicated to providing support and information to anyone diagnosed with or caring for someone with an Eosinophilic Gastrointestinal Disorder (EGID) including Eosinophilic oEsophagitis (EoE). ausEE is committed to raising public awareness and supporting the medical community for further research into eosinophilic disorders in Australia. We have an active facebook group providing valuable support to adults with EGIDs and parents and caregivers of children diagnosed with an EGID.

We offer free patient resources including children's picture books on EoE, EGID medical brochures and patient information folders. For more information, please visit www.ausee.org



Australia: www.amsl.com.au

New Zealand: www.nzms.co.nz

At Australasian Medical and Scientific Ltd (AMSL) and New Zealand Medical and Scientific Ltd (NZMS) we deliver leading allergy solutions to allergists, dermatologists and other medical practitioners throughout Australia and New Zealand.

Our range includes Sub Lingual, Subcutaneous and Tablet Immunotherapy Vaccines; Skin Prick Test allergens; ready to use and open type Patch Test Systems; intradermal allergen tests for penicillin, amoxicillin and clavulanic acid; RhinoLight for treatment of allergic rhinitis; lancets and accessories. Our range includes leading brands such as ALK Abello, SmartPractice, Lincoln Diagnostics and Diater.

Exhibitor Directory

We pride ourselves on our experience and expertise in the field of allergy diagnosis and immunotherapy as well as our reliable and excellent service.



www.autoimmune.org.au

ARRC was established in 1989, to provide people living with systemic and organ specific autoimmune illnesses education and support services as well as access to research.

ARRC services aim to reduce the impact and disease burden of illness by educating patients, carers, family and the general community on autoimmune illness, promoting healthy lifestyles and better self-management choices. Programs are designed to improve overall health, quality of life and life potential whilst maintaining a balance between medical treatments, illness understanding and self-management techniques.

ARRC offers a wide range of educational resource materials and education seminars for patients and health professionals.
www.autoimmune.org.au

Baxter

www.baxterhealthcare.com.au

Baxter Healthcare innovates, develops, manufactures and markets products for people with haemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The company's diverse portfolio is focused on treatments that save and sustain lives. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to research and create products that advance patient care worldwide.

For further information visit www.baxterhealthcare.com.au

Baxter Healthcare Pty Ltd. 1 Baxter Drive, Old Toongabbie, NSW 2146. Australia

CSL Behring

www.cslbehring.com.au

CSL Behring has been the national fractionator of plasma-derived therapeutics for the Governments of Australia and New Zealand since 1952 and 1963 respectively. Much of CSL Behring's focus during this time has been on delivering a world class and broad range of plasma-derived therapies specifically designed to meet the needs of healthcare professionals and patients in both these countries.

CSL Behring, through its research and development program, is committed to ensuring continued world class standards of quality, product yields, patient convenience and manufacturing efficiency in our broad portfolio of plasma-derived therapies. An example of this commitment is the use of modern manufacturing technologies for our products and the inclusion of at least two dedicated and complementary pathogen reduction steps in the manufacturing process of each product in Australia and New Zealand.

Diagnostic Solutions

www.diagnosticsolutions.com.au

Diagnostic Solutions is a leading distributor of high quality, innovative automated systems for autoimmune diagnostic testing across Australia and New Zealand. The Image Navigator® from Immuno Concepts is the most advanced automated IFA system today. With true sample traceability, fast positive / negative screening combined with interfacing to the CARIS™/DSR™ Systems using the DEESSE software the system can provide workflow streamlining capability for your laboratory.

Australia: 1300 788 003 New Zealand: 0800 448 018

ego the science of healthy skin™

www.egopharm.com

Ego Pharmaceuticals is an Australian family owned and operated company who for more than 50 years have specialised in the manufacture of quality skincare products such as market leaders

'QV', 'Sunsense', 'Pinetarsol', 'DermAid' and 'Moov'.

ASCIA 2014 CONFERENCE

The QV range of gentle moisturisers and cleansers has been scientifically formulated for those who suffer from dry or sensitive skin conditions. The entire QV range is free from colour, fragrance, propylene glycol, lanolin and its derivatives making it ideal for the most sensitive skin types.

ENT TECHNOLOGIES



www.enttech.com.au

ENT Technologies Pty Ltd is a wholly Australian owned business which specialises in the formulation, development and delivery of novel pharmaceutical preparations for the management of both acute and chronic pathologies of both nasal and sinus cavities.

ENT Technologies has pioneered the introduction of FLO –a range of sterile, preservative-free multidose nasal sprays in Australia. It was also first to formulate sinus irrigations with Ringers solution (FLO Sinus Care) rather than just salt and sodium bicarbonate and to further develop this preservative free technology into a very low ionic strength irrigation solution which would not interfere with innate immunity in the paranasal sinuses.

ENT Technologies welcomes discussion with surgeons and Immunologists who have unique requirements for their patients. If we can help, we will.



www.gsk.com.au

GlaxoSmithKline is a global research-based pharmaceutical and healthcare company with a mission to improve the quality of human life by enabling people to do more, feel better and live longer. In Australia we have improved people's wellbeing by delivering the highest quality medicines, vaccines and over-the-counter healthcare products since 1886. We provide about 1700 skilled jobs across the country, working with researchers and doctors to discover new ways of treating and preventing disease. In 2012 we invested \$54 million in local research and development, and supplied \$521 million to Australia's pharmaceutical and medicinal exports.



www.haeaustralasia.org.au

HAE Australasia Ltd is a not for profit organisation, founded by HAE patients and caregivers and is dedicated to improving the quality of life of those living with Hereditary Angioedema (HAE) in Australia and New Zealand.

HAE Australasia provides education to patients, carers and health care providers, raises the awareness of HAE in the medical and general communities and assists research organisations with their studies into causes, prevention and treatment of HAE.

HAE Australasia is also looking at ways to make treatment and medications more accessible for patients across Australia and New Zealand.



www.idfa.org.au

Immune Deficiencies Foundation of Australia (IDFA) is the patient organisation for people affected by Primary Immune Deficiencies in Australia. IDFA provides education, information, advocacy,

communication and support to members. IDFA is governed by a Board of Directors which includes two leading Australian Immunologists (Paediatric and Adult). IDFA is a member of IPOPI (International Patient Organisation for Primary Immunodeficiencies) and has representation on the IPOPI Board. IDFA welcomes membership from Immunologists and other Health Professionals.

For further information, email christine.jeffery@idfa.org.au, call 0409 945 114 or visit our website.

Exhibitor Directory



www.idfnz.org.nz

Immune Deficiencies Foundation of New Zealand (IDFNZ) is a registered charity which has served patients of all ages with diagnosed Primary Immune Deficiency (PID) disorders since 1989.

IDFNZ offers individual patient support, education, advocacy and information. IDFNZ also sponsors medical and scientific research, and promotes awareness of PID to the general public and health professionals including visiting speaker and awareness programmes. IDFNZ is governed by a volunteer Board which includes representatives from our medical advisory panel, comprising of leading medical professionals specialising in PID disorders. IDFNZ is a foundation member of the International Patient Organisation for Primary Immune Deficiencies (IPOP).



www.meda.com.au

MEDA AB is a leading international specialty pharmaceutical company. Our products are sold in 120 countries worldwide and the company is represented by its own organizations in 60 countries.

With Australian headquarters in Sydney, MEDA is a fast growing global pharmaceutical company with an exciting portfolio of products in niche markets. Our company culture embraces innovation and creativity. We celebrate new ideas and getting things done.

We are committed to quality products and happy customers. The MEDA share is listed under Large Cap on the Nasdaq OMX Nordic Stock Exchange in Stockholm. Find out more, visit www.meda.se or www.meda.com.au



www.msd-australia.com.au

Today's MSD is a global healthcare leader working to help the world be well. MSD is a tradename of Merck & Co., Inc., with headquarters in Whitehouse Station, N.J., U.S.A. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with

customers and operate in more than 140 countries to deliver innovative health solutions.

We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.msd-australia.com.au.



www.neilmed.com

NeilMed Pharmaceuticals, manufacturers of allergy & sinus relief products. NeilMed's Sinus Rinse Kit, a soothing saline nasal irrigation system with 60 packets of preservative free, isotonic, pH

balanced mixture, irrigation bottle, custom designed cap. Highly effective for rhinosinusitis, allergies, and most beneficial for post FESS patients. NeilMed's NasaFlo, free flowing gravity method

to nasal irrigation. NeilMed's NasoGel, a soothing saline gel for prolonged moisturization of dry nasal passages. NeilMed's NasaMist, buffered, preservative free nasal spray, isotonic and hypertonic available. NasaDrops Ampoules with Aspirators Saline ampoules for stuffy, congested or dry noses for babies, children & adults. Tel: 1300 652 148



www.nestle-hcp.com.au



www.nestlehealthscience.com.au

Nestlé is the world's leading Nutrition, Health and Wellness company. Through integrating scientific and research expertise, Nestlé Nutrition aims to pioneer the development and application of evolving science to help infants & children develop to their full potential plus create a new role for nutrition in disease prevention and management. Together Nestlé Health Science & Nestlé Infant Nutrition offer high quality nutrition products for the crucial first years of life & nutritional solutions for people with specific dietary needs related to illnesses, disease states or the special challenges of different life stages.

As a long-time sponsor of ASCIA please come and visit us during this year's meeting to find out more about our product range.



www.novartis.com.au

Novartis is helping Australians live healthier lives. Our medicines focus on critical disease areas including cardiovascular and metabolic diseases, ophthalmology, neuroscience, respiratory diseases and oncology. Novartis' history in Australia goes back over 50 years. We are committed to research and development and since 2007 Novartis has invested 20% of its net pharmaceutical sales globally in R&D – in Australia we invest around \$AUD 30 million annually.

Learn more at: www.novartis.com.au

Novartis Pharmaceuticals Australia Pty Limited

54 Waterloo Road North Ryde NSW 2113

Phone +61 2 9805 3555

Fax +61 2 9887 4551

ABN: 18 004 244 160



www.neocate.com.au



www.danonenutriciaprofessional.com.au

Nutricia leads the way through years of experience in providing a comprehensive portfolio for Advanced Allergy Management. Our products are scientifically researched for protection from and management of cows' milk protein allergy.

We look forward to discussing with you how Nutricia's expertise and comprehensive allergy portfolio can assist you. By offering an unmatched superior nutritional profile, Nutricia can help you make a difference to the lives of the infants, children and mothers you care for along their allergy journey.

Visit the Nutricia Advanced Allergy Management stand 5 and 6 to find out more.



For the safe and optimal use of human proteins

www.octapharma.com.au

Octapharma specialises in the development and production of human proteins derived from plasma and recombinant technologies. Using cutting-edge purification and viral inactivation techniques we live by our mission of "for the safe and optimal use of human proteins." We provide life saving therapies to our patients in the treatment of multifarious diseases in Haematology, Immunotherapy, Intensive Care and Emergency Medicine.

Octapharma operates and manufactures products to the highest standards of quality and safety required by physicians, patients and regulatory authorities globally.

Please contact Octapharma Australia for more information:
www.octapharma.com.au



www.shireaustralia.com.au

As one of the world's leading specialty biopharmaceutical companies, Shire's purpose is to enable people with life-altering conditions to lead better lives. Shire's Rare Diseases Business Unit focuses on innovating, developing and providing treatments that enhance the quality of life of patients suffering from rare diseases. Established in 2008, Shire Australia offers products in Fabry and Gaucher Diseases and Hereditary Angioedema. Shire also provides products in the areas of Hyperphosphataemia in Chronic Renal Disease, Essential Thrombocythaemia, mild to moderate active Ulcerative Colitis and Attention Deficit Hyperactivity Disorder.

Level 6, Avaya House, 123 Epping Road, North Ryde, NSW, 2113.

Website: www.shireaustralia.com.au Telephone: 1800012612

Email: enquiriesaustralia@shire.com

Exhibitor Directory



www.stallergenes.com

For over half a century Stallergenes has been a leader and pioneer in allergen immunotherapy. With a strong commitment to research and development, Stallergenes dedicates close to 20% of its turnover each year to the development of innovative and evidence-based treatments.

Locally, Stallergenes Australia is dedicated to partnering with the Australasian allergist community to address the unmet need of patients suffering from moderate to severe allergic respiratory disease. Our investments are oriented to this cause and are seen through consistent support and grants we provide, along with delivering the only TGA and Medsafe registered AIT treatments on the ANZ market.



www.takedaaustralia.com.au

Takeda, with a long and rich history spanning 231 years, is Japan's largest pharmaceutical company and the 15th largest worldwide. Takeda's mission is to 'strive towards better health for people worldwide through leading innovation in medicine.'

To achieve this goal, the Company is pursuing new drug discovery that overcomes the barriers to technical innovation currently seen in the pharmaceutical industry in order to develop a strong pipeline of products that offer outstanding efficacy and safety for people worldwide.



www.mastocytosis.com.au

TAMS was formed in 2011 and is working to:

- Provide a network of support for patients living with Mastocytosis or a Mast Cell Activation Disorder (MCAD) and their carers
- Connect patients to medical practitioners and specialists with knowledge of Mastocytosis and MCAD

- Link together with similar associations worldwide to collectively gather research data, share resources and knowledge in the hope of greater understanding, treatment practices, medications and overall improved health outcomes for those living with Mastocytosis or MCAD.

Education, Advocacy, Support, Research

www.mastocytosis.com.au

Email: info@mastocytosis.com.au



www.werfen.com

We are leaders in the development of new autoimmune technologies and diagnostic markers.

We manufacture IVD systems and reagents that are used in clinical laboratories and hospitals around the world.

For more than 25 years, Inova Diagnostics has collaborated with clinical researchers to develop biomarkers that help advance the care of autoimmune disease patients. We are redefining autoimmunity to deliver solutions that anticipate the needs of laboratories and improve the efficiency and quality of testing.

Inova Diagnostics is part of Werfen, a global leader in IVD with a long term commitment to providing high quality, innovative solutions for hospitals and clinical laboratories to enhance patient care. Werfen companies include Inova Diagnostics, Instrumentation Laboratory, Biokit and Systelab.

The advertising space for the ASCIA 2015 Conference (see opposite page) has been supported by

CSL Behring

a Diamond sponsor of ASCIA in 2014 and a founding sponsor of AIFA.

ASCIA 2015 CONFERENCE

26th Annual Conference of the Australasian Society
of Clinical Immunology and Allergy
Adelaide Convention Centre | 9-12 September 2015

www.ascia2015.com

ascia

australasian society of clinical immunology and allergy

www.allergy.org.au

ASCIA is the peak professional body for allergy and
clinical immunology in Australia and New Zealand



25 years of ASCIA Annual Scientific Meetings 1990 – 2014



- 1990 Melbourne VIC (Hilton on the Park, April 29 - May 1)
- 1991 Perth, WA (Burswood Hotel, December 1-3)
- 1992 Cairns, QLD (Hilton Hotel, September 13-15)
- 1993 Sydney, NSW (Darling Harbour, April 29 – May 1)
- 1994 Canberra, ACT (Lakeside Hotel, December 2-5)
- 1995 Sydney, NSW (Regent Hotel, October 30-November 3) held with TPAIS
- 1996 Adelaide, SA (Hyatt Hotel, December 5-7)
- 1997 Wellington, NZ (Convention Centre, April 5-8) held with TSANZ
- 1998 Brisbane, QLD (Sheraton Hotel, August 28-30)
- 1999 Uluru, NT (Ayers Rock Resort, September 24-27)
- 2000 Sydney, NSW (Convention Centre, October 15-20) (held as part of the 17th World Allergy Congress)
- 2001 Perth, WA (Sheraton Hotel, September 28-30)
- 2002 Adelaide, SA (Hilton Hotel, September 27-29)
- 2003 Melbourne, VIC (Sheraton Southgate Hotel, September 10-12)
- 2004 Gold Coast, QLD (Marriott Hotel, September 8-10)
- 2005 Queenstown, NZ (Millennium Hotel, August 31 - September 2)
- 2006 Sydney, NSW (Manly Pacific Hotel, September 7-9)
- 2007 Fremantle, WA (Esplanade Hotel, November 14-16)
- 2008 Melbourne, VIC (Park Hyatt Hotel, November 12-14)
- 2009 Adelaide, SA (Adelaide Convention Centre, September 16-18)
- 2010 Gold Coast, QLD (Gold Coast Convention & Exhibition Centre, September 1-4)
- 2011 Sydney, NSW (Sydney Convention & Exhibition Centre, Darling Harbour, September 6-10)
- 2012 Wellington, NZ (Wellington Town Hall, September 5-8)
- 2013 Perth, WA (Perth Convention and Exhibition Centre, September 10-14)
- 2014 Melbourne, VIC (Melbourne Convention Centre, September 10-13)